IL1B and atherosclerosis: A large clinical study showed that controlling inflammation by blocking IL-1β could suppress atherosclerosis and reduce cardiovascular events (Ridker et al., 2017); however, subsequent research revealed that IL-1β has atheroprotective effects in mice (Gomez et al., 2018), which suspended further clinical research.